This mechanism is consistent with recent observations that the epigenetic targeted drugs 5-azacytidine and the LBH589 HDAC inhibitor can act additively, or in some cases synergistically with ING1 in killing cells in breast cancer cell and animal models [20]. This evidence concerns the gene HDAC9 and breast carcinoma.